Johnson & Johnson (JNJ) raised its quarterly dividend from $1.24 to $1.30 per share (5% increase) and extended its consecutive dividend hike streak to 63 years, yielding 2.14% annually with a sustainable 46.7% payout ratio and $19.7 billion in free cash flow. Pfizer (PFE) carries payout ratio risk at 118.6% despite higher yield, while Merck (MRK) lacks Johnson & Johnson’s breadth and reliability track record.
Johnson & Johnson’s diversified portfolio of medicines, medical devices, and consumer health products spanning 28 platforms generating over $1 billion annually positions it to sustain dividend growth through patent expirations and litigation challenges that pressure competitors.
A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here.
Markets have delivered plenty of twists lately, with inflation cooling but growth uneven and volatility still lurking around every earnings corner. Smart investors know one truth holds steady: reliable income beats hype every time.
That is why you should consider owning a healthcare giant that has raised its dividend through recessions, pandemics, and patent cliffs — without missing a beat. Johnson & Johnson (NYSE:JNJ) is a Dividend King that doesn’t just pay; it delivers consistency that lets shareholders sleep soundly while the broader market twists.
Johnson & Johnson has hiked its dividend for 63 consecutive years, and stands poised to deliver its 64th annual increase when it reports first-quarter 2026 earnings before the market opens on April 14. That track record isn’t luck — it’s the result of disciplined capital allocation across its diversified portfolio of medicines, medical devices, and consumer health products.
Read: Data Shows One Habit Doubles American’s Savings And Boosts Retirement
Most Americans drastically underestimate how much they need to retire and overestimate how prepared they are. But data shows that people with one habit have more than double the savings of those who don’t.
Last year, Johnson & Johnson raised its quarterly payout from $1.24 to $1.30 per share, a near-5% increase. The stock now yields 2.14% at an annualized $5.20 per share. Over the past decade, it has delivered 5% compounded annual growth. The payout ratio also sits at a comfortable 46.7%, leaving ample room for reinvestment or further hikes. In short, this isn’t a high-yield trap—it’s a machine built for steady raises for decades to come.
Let’s look at the numbers that back this up. Johnson & Johnson’s full-year 2025 results showed reported sales of $94.2 billion, up 6% from 2024. Operational growth hit 5.3%, even after accounting for the loss of exclusivity on Stelara. Innovative Medicine alone topped $60 billion in sales for the first time, with 13 brands growing double digits.
Adjusted earnings reached $10.79 per share, an 8.1% increase from the prior year. Free cash flow came in at approximately $19.7 billion, funding $12.4 billion in dividends paid to shareholders and more than $32 billion in R&D plus strategic acquisitions. The balance sheet remains fortress-strong, with net debt around $28 billion against nearly $20 billion in cash and marketable securities.
No matter how you look at it, these figures show a company that generates cash it can afford to share — without stretching.
Investors often chase higher yields elsewhere in healthcare, but Johnson & Johnson stacks up favorably when you compare the full picture. Here’s how it lines up against two key rivals, based on the latest available data:
Metric
Johnson & Johnson
Pfizer (NYSE:PFE)
Merck (NYSE:MRK)
Dividend Yield
2.14%
6.20%
2.88%
Payout Ratio
46.7%
118.6%
45.8%
Consecutive Dividend Increases
63 years
16 years
15 years
5-Year Average Annual Dividend Growth
5.25%
2.5%
7%
Pfizer’s sky-high yield comes with real risk — its payout ratio above 100% signals pressure ahead. Merck offers solid growth but lacks Johnson & Johnson’s breadth and decades-long reliability. Johnson & Johnson also trades at a normalized P/E of about 22.45, a reasonable premium for its lower volatility and proven cash generation.
That said, no stock is risk-free. Ongoing litigation and patent expirations remain watch items, but Johnson & Johnson’s diversified pipeline — 28 platforms now generating over $1 billion annually — positions it to navigate those challenges.
Don’t bet against this Dividend King. With earnings due April 14 and the 64th dividend increase on the horizon, Johnson & Johnson offers retail investors a rare combination: 2.14% yield today, low payout ratio for future growth, and a business model built to compound wealth quietly. Add it for the income and the peace of mind — your portfolio will thank you.
Most Americans drastically underestimate how much they need to retire and overestimate how prepared they are. But data shows that people with one habit have more than double the savings of those who don’t.
And no, it’s got nothing to do with increasing your income, savings, clipping coupons, or even cutting back on your lifestyle. It’s much more straightforward (and powerful) than any of that. Frankly, it’s shocking more people don’t adopt the habit given how easy it is.
-1024x683.jpg "Judge Who Helped Violent Illegal Alien Evade ICE Faces New Test")
-1024x683.jpg "Montana Puts Democrats in a Bind as Senate Hopes Fade")
